David Fandrei

Leipzig, SN, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications

Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma.

Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma.

Journal: Haematologica
Published: April 15, 2026

We included a total of 87 patients who received CAR T-cell therapy: 54 with none/mild chronic kidney disease (CKD) and 33 with moderate/severe CKD.

We included a total of 87 patients who received CAR T-cell therapy: 54 with none/mild chronic kidney disease (CKD) and 33 with moderate/severe CKD.

Journal: Transplantation and cellular therapy
Published: February 10, 2026

Fertility management and outcomes after CAR T-cell therapy: an international survey from the Cellular Therapy and Immunobiology working party of the European Society for Blood and Marrow Transplantation.

Fertility management and outcomes after CAR T-cell therapy: an international survey from the Cellular Therapy and Immunobiology working party of the European Society for Blood and Marrow Transplantation.

Journal: EClinicalMedicine
Published: February 04, 2026

Flare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myeloma.

Flare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myeloma.

Journal: Leukemia
Published: January 31, 2026

Pharmacokinetics of CAR T cells in multiple myeloma - the good, the bad, and the ugly.

Pharmacokinetics of CAR T cells in multiple myeloma - the good, the bad, and the ugly.

Journal: Leukemia
Published: January 08, 2026

Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

Journal: Blood cancer discovery
Published: December 03, 2025

MyCARdiac score: integrating cardiac imaging and biomarkers to predict outcomes in RRMM patients receiving cilta-cel.

MyCARdiac score: integrating cardiac imaging and biomarkers to predict outcomes in RRMM patients receiving cilta-cel.

Journal: Leukemia
Published: October 14, 2025

Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single-cell profiling in anti-BCMA CAR T-treated myeloma.

Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single-cell profiling in anti-BCMA CAR T-treated myeloma.

Journal: HemaSphere
Published: September 11, 2025

Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy.

Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy.

Journal: Blood
Published: May 05, 2025

A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma.

A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma.

Journal: Cancer cell
Published: May 05, 2025

Prognostic Implications of Splenomegaly in BCMA-Directed CAR T-Cell Therapy for Relapsed Myeloma.

Prognostic Implications of Splenomegaly in BCMA-Directed CAR T-Cell Therapy for Relapsed Myeloma.

Journal: Transplantation and cellular therapy
Published: March 28, 2025

Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma.

Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma.

Journal: HemaSphere
Published: February 13, 2025
Showing 1-12 of 19

Last Updated: 09/26/2026